Brief: ALX Oncology Announces First Patients Dosed With Evorpacept And Sarclisa As Part Of Randomized Phase 1/2 UMBRELLA Study With Sanofi

ALX Oncology Holdings

04/09/2024 13:13

Sept 4 (Reuters) - ALX Oncology Holdings Inc  ALXO.O :
    * ALX ONCOLOGY ANNOUNCES FIRST PATIENTS DOSED WITH
EVORPACEPT AND
SARCLISA AS PART OF RANDOMIZED PHASE 1/2 UMBRELLA STUDY WITH
SANOFI

Source text for Eikon:  ID:nGNX7dXSkZ 
Further company coverage:  ALXO.O 

 ((Reuters.Brief@thomsonreuters.com;))